Updated results from ASCENT-J02, a study of sacituzumab govitecan in Japanese participants with metastatic triple-negative breast cancer
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Sacituzumab govitecan (SG) is approved in Japan for pretreated unresectable or recurrent triple-negative breast cancer (TNBC). ASCENT-J02 is an open-label, phase 1/2 study of SG in Japanese patients. At primary analysis (median follow-up, 6.1 months) of the metastatic TNBC (mTNBC) cohort (n = 36), objective response rate (ORR) was 25.0% (95% CI: 12.1-42.2; P = 0.0077), median progression-free survival (PFS) was 5.6 months (95% CI: 3.9-not reached), and SG had a manageable safety profile, consistent with the global phase 3 ASCENT study. We report updated outcomes, including the first overall survival (OS) results. METHODS: Patients with pretreated mTNBC received 10 mg/kg SG intravenously on days 1 and 8 of 21-day cycles. The primary endpoint was independent review committee-assessed ORR (RECIST v1.1). Secondary endpoints included PFS, duration of response, time to response, OS, and safety. RESULTS: With median follow-up of 15.9 months for 36 patients with mTNBC, ORR with SG was 31% (95% CI: 16-48); four complete responses were observed. Median PFS was 5.6 months (95% CI: 3.9-15.8), and median OS was 15.9 months (95% CI: 10.4-22.4). No treatment-emergent adverse events (TEAEs) led to treatment discontinuation or death. Grade ≥ 3 TEAEs were observed in 26 (72%) patients; most frequent were neutropenia (58%), leukopenia (36%), and diarrhea (11%). CONCLUSIONS: With longer follow-up, SG continued to demonstrate efficacy and safety consistent with the global ASCENT study. These results further support the use of SG in Japanese patients with pretreated mTNBC.
Institutions: Kyoto University Hospital, National Cancer Center Hospital East, Tohoku University Hospital, Osaka International Cancer Institute, Kumamoto University Hospital, Nagoya University, Hyogo Prefectural Cancer Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, National Cancer Center Hospital, National Center for Global Health and Medicine, Gilead Sciences (United States), Gilead Sciences (Japan), Nagoya City University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,590
Funder: Gilead Sciences
OpenAlex ID: W7231767640
